Literature DB >> 9148432

[The therapeutic management of radiogenic oral mucositis].

W Dörr1, I Dölling-Jochem, M Baumann, T Herrmann.   

Abstract

BACKGROUND: Acute reactions of oral mucosa are a frequent side effect of radiotherapy, which often necessitates interruption of the treatment. Marked proliferation of tumor stem cells during treatment interruptions may occur in squamous cell carcinomata, which represent the majority of tumors in the head and neck area. Hence a fatal consequence of treatment breaks may be a significant decrease in tumor cure rates. Furthermore, marked acute responses frequently result in increased late sequelae ("consequential damage"). Therefore, amelioration of the mucosal response aiming at avoiding treatment breaks and at reduction of late reactions could definitely increase the therapeutic success of radiation treatment. PATIENTS AND
METHOD: Various possibilities for the therapeutic management of radiation-induced oral mucositis with a symptomatic or radio- and epithelial biological background are summarized and presented systematically.
RESULTS: A variety of prophylactic and therapeutic methods have been proposed for the management of acute radiation reactions of the oral mucosa. Frequently, their efficacy has been established for chemotherapy or in combination with other immunosuppressive treatments. Hence, systematical rather than local effects have to be considered.
CONCLUSIONS: In general, prophylaxis of oral mucositis is mainly based on dental restoration or edentation, in combination with frequent oral hygienic measures after the meals and with antiseptic mouthwashes. Intensive personal care is recommended. The necessity of a percutaneous endoscopic gastrostoma is dependent on the status of the patient and on size and localization of the treatment area, i.e. the impairment of food uptake which is to be expected. Therapeutic intervention is restricted to local or systemic treatment of pain and local application of antimycotics and antibiotics.

Entities:  

Mesh:

Year:  1997        PMID: 9148432     DOI: 10.1007/bf03039287

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  67 in total

1.  Smoking and mucosal reactions to radiotherapy.

Authors:  T Rugg; M I Saunders; S Dische
Journal:  Br J Radiol       Date:  1990-07       Impact factor: 3.039

2.  Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors.

Authors:  C S Potten; G Owen; D Hewitt; C A Chadwick; H Hendry; B I Lord; L B Woolford
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

3.  What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation?

Authors:  K R Trott; J Kummermehr
Journal:  Radiother Oncol       Date:  1985-01       Impact factor: 6.280

4.  Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy.

Authors:  A Prada; F Chiesa
Journal:  Int J Tissue React       Date:  1987

5.  Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx.

Authors:  J H Kim; F C Chu; V Lakshmi; R Houde
Journal:  Am J Clin Oncol       Date:  1986-04       Impact factor: 2.339

6.  Effects of chlorhexidine during immunosuppressive chemotherapy. A preliminary report.

Authors:  J S Rutkauskas; J W Davis
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1993-10

7.  [Laser therapy in the prevention and treatment of mucositis caused by anticancer chemotherapy].

Authors:  G Ciais; M Namer; M Schneider; F Demard; N Pourreau-Schneider; P M Martin; M Soudry; J C Franquin; H Zattara
Journal:  Bull Cancer       Date:  1992       Impact factor: 1.276

8.  Prophylactic administration of indomethacin for irradiation esophagitis.

Authors:  N Nicolopoulos; A Mantidis; E Stathopoulos; S Papaodysseas; J Kouvaris; H Varveris; C Papavasiliou
Journal:  Radiother Oncol       Date:  1985-01       Impact factor: 6.280

9.  Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx.

Authors:  J Overgaard; M Hjelm-Hansen; L V Johansen; A P Andersen
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

10.  A convenient method for guarding against localized mucositis during radiation therapy.

Authors:  R Wang; A Boyle
Journal:  J Prosthodont       Date:  1994-12       Impact factor: 2.752

View more
  6 in total

1.  Prospective study of the long term change of the oral flora after radiation therapy.

Authors:  B Al-Nawas; K A Grötz
Journal:  Support Care Cancer       Date:  2005-11-30       Impact factor: 3.603

2.  Effects of bone marrow or mesenchymal stem cell transplantation on oral mucositis (mouse) induced by fractionated irradiation.

Authors:  M Schmidt; J Haagen; R Noack; A Siegemund; P Gabriel; W Dörr
Journal:  Strahlenther Onkol       Date:  2014-01-24       Impact factor: 3.621

Review 3.  [Prevention and therapy of acute radiation-related morbidity of the skin and mucosa. II, Recommendations of the literature].

Authors:  J S Zimmermann; P Niehoff; R Wilhelm; R Schneider; G Kovács; B Kimmig
Journal:  Strahlenther Onkol       Date:  1998-04       Impact factor: 3.621

4.  [Prevention of radiochemotherapy-induced mucositis. Value of the prophylactic mouth rinsing with PVP-iodine solution].

Authors:  I A Adamietz; R Rahn; H D Böttcher; V Schäfer; K Reimer; W Fleischer
Journal:  Strahlenther Onkol       Date:  1998-03       Impact factor: 3.621

5.  Long-term oral Candida colonization, mucositis and salivary function after head and neck radiotherapy.

Authors:  K A Grötz; S Genitsariotis; D Vehling; B Al-Nawas
Journal:  Support Care Cancer       Date:  2003-08-09       Impact factor: 3.603

6.  The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium.

Authors:  W Dörr; K Spekl; C L Farrell
Journal:  Cell Prolif       Date:  2002-08       Impact factor: 6.831

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.